CXA-10

Phase 2Small molecule

CComplexa, Inc.

CXA-10 is one of 118 small molecule programs targeting Kidney Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney InjuryActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

AsthmaActive, not recruiting

Focal Segmental GlomerulosclerosisActive, not recruiting

Kidney InjuryPhase 1

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Focal Segmental GlomerulosclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Xolair

Roche

Preclinical

25 2

Singulair

AstraZeneca

Preclinical

17 3

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 4

CXA-10

CComplexa, Inc.

Phase 2

2 5

Spiriva

Boehringer Ingelheim

Preclinical

8 6

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 7

Arcoxia

Aciphex

2 9

Atrovent

Boehringer Ingelheim

Preclinical

2 10

Aclidinium Bromide

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Asthma

NCT03762395

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Terminated·CComplexa, Inc.·Phase 2·NCT03449524·69 enrolled

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Terminated·CComplexa, Inc.·Phase 2·NCT04053543·33 enrolled

Oral CXA-10 in Pulmonary Arterial Hypertension

Terminated·GGladwin, Mark, MD·Phase 2·NCT04125745·1 enrolled

Asthma2 trials

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT03762395·60 enrolled

Anti-Inflammatory Lipid Mediators in Asthma

Withdrawn·SSally E. Wenzel MD·Phase 2·NCT03680976

Kidney Injury1 trial

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

Completed·CComplexa, Inc.·Phase 1·NCT02248051·12 enrolled

Focal Segmental Glomerulosclerosis1 trial

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed·CComplexa, Inc.·Phase 2·NCT03422510·33 enrolled

Oral1 trial

Oral CXA-10 Study in Healthy Volunteers

Completed·CComplexa, Inc.·Phase 1·NCT02313064·40 enrolled

3 more indications

Interaction1 trial

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

Completed·CComplexa, Inc.·Phase 1·NCT02547402·10 enrolled

Obese1 trial

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

Completed·CComplexa, Inc.·Phase 1·NCT02460146·43 enrolled

Unspecified1 trial

Study of CXA-10 in Healthy Volunteers

Completed·CComplexa, Inc.·Phase 1·NCT02127190·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for CXA-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CXA-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CXA-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Complexa, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CComplexa, Inc.

CXA-10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

Asthma2 trials

Kidney Injury1 trial

Focal Segmental Glomerulosclerosis1 trial

Oral1 trial

Interaction1 trial

Obese1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News